Change in ADS ratio

AstraZeneca PLC - Change in ADS ratio

AstraZeneca PLC (the "Company") today announces an intended ratio change to its
NYSE-listed sponsored Level 2 American Depositary Receipt ("ADR") programme. The
current ratio is one (1) American Depositary Share ("ADS") per one (1) Ordinary
Share. The new ratio will be two (2) ADSs per one (1) Ordinary Share. The
expected effective date for the ratio change is 27 July 2015. There will be no
change to the underlying Ordinary Shares.

ADS holders at the close of business New York time on the record date, 22 July
2015, will receive a distribution of one additional ADS for every ADS held. The
new ADSs are expected to be distributed on 24 July 2015. No action is required
by ADS holders to effect this change.

Contact details for Citibank, N.A., the Company's ADR depositary, can be found
below.

A C N Kemp

Company Secretary

26 June 2015



CONTACT

Citibank Shareholder Services

PO Box 43077   Tel (toll free in the   US): +1-888-697-8018
Providence     Tel (outside the US): +1-781-575-4555
RI 02940-3077
US

 Media Enquiries

Esra Erkal-Paler  +44 20 7604 8030   (UK/Global)
Jacob Lund        +46   8 553 260 20 (Sweden)
Michele Meixell   + 1 302 885 6351 (US)

Investor Enquiries

UK
Thomas                                  +44 20 7604 8199  mob: +44 7818 524185
Kudsk
Larsen
Eugenia    Respiratory,   Inflammation  +44 20 7604 8233  mob: +44 7884 735627
Litz       and Autoimmunity
Nick       Cardiovascular andMetabolic  +44 1763 263 994  mob: +44 7717 618834
Stone      Disease
Karl Hård  Oncology                     +44 20 7604 8123  mob: +44 7789 654364
Craig      Infection,   Neuroscience    +44 20 7604 8591  mob: +44 7881 615764
Marks      and Gastrointestinal
           Disease
Christer                                +44 20 7604 8126  mob: +44 7827 836825
Gruvris
US
Dial /                                  301-398-3251       866-381-7277
Toll-Free